Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Q32 Bio ( (QTTB) ) has shared an update.
Q32 Bio announced encouraging results from its SIGNAL-AA Phase 2a trial for bempikibart in treating alopecia areata, demonstrating clinical activity and a favorable safety profile, prompting plans to expand the trial. However, its SIGNAL-AD trial for atopic dermatitis did not meet its primary endpoint, leading the company to plan a review of the results.
More about Q32 Bio
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis.
YTD Price Performance: 123.13%
Average Trading Volume: 109,714
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $297.3M
See more data about QTTB stock on TipRanks’ Stock Analysis page.
